Tags

Type your tag names separated by a space and hit enter

24-hour intraocular pressures with brimonidine purite versus dorzolamide added to latanoprost in primary open-angle glaucoma subjects.
Ophthalmology. 2005 Apr; 112(4):603-8.O

Abstract

OBJECTIVE

To evaluate the 24-hour efficacy of brimonidine purite versus dorzolamide, each added to latanoprost.

DESIGN

Double-masked, 2-center, prospective, crossover comparison.

PARTICIPANTS

Primary open-angle glaucoma (POAG) subjects.

METHODS

Subjects were randomized to brimonidine purite or dorzolamide, each given twice daily, for the first 6-week treatment period after a 6-week latanoprost run-in. Subjects began the opposite treatment for the second 6-week period after a 6-week latanoprost-only treatment between periods. Intraocular pressure (IOP) was measured at 8 am, 12 pm, 4 pm, 8 pm, 12 am, 4 am, and 8 am at each baseline and at the end of each treatment period. This study provided an 80% power that a 1.5-mmHg difference could be excluded between groups if 27 subjects completed the study. A standard deviation (SD) of 2.8 mmHg was assumed.

MAIN OUTCOME MEASURES

Twenty-four-hour efficacy of intraocular pressures of brimonidine purite versus dorzolamide, each added to latanoprost.

RESULTS

In 31 completed subjects, the baseline mean diurnal 24-hour IOP (+/- SD) was 19.0+/-1.7 mmHg for brimonidine purite and 19.0+/-1.6 mmHg for dorzolamide (P = 0.52). The 8 am IOP after 6 weeks of therapy was 18.4+/-2.1 mmHg for brimonidine purite and 18.9+/-1.9 mmHg for dorzolamide (P = 0.40). The mean diurnal IOP was 16.9+/-1.5 mmHg for brimonidine purite and 16.8+/-1.5 mmHg for dorzolamide (P = 0.66). Dorzolamide caused a more bitter taste (P = 0.01) than brimonidine purite.

CONCLUSIONS

This study suggests that brimonidine purite and dorzolamide, added to latanoprost, have similar efficacy and safety in POAG or ocular hypertensive subjects.

Authors+Show Affiliations

University Department of Ophthalmology, AHEPA Hospital, Thessaloniki, Greece.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15808251

Citation

Konstas, Anastasios G P., et al. "24-hour Intraocular Pressures With Brimonidine Purite Versus Dorzolamide Added to Latanoprost in Primary Open-angle Glaucoma Subjects." Ophthalmology, vol. 112, no. 4, 2005, pp. 603-8.
Konstas AG, Karabatsas CH, Lallos N, et al. 24-hour intraocular pressures with brimonidine purite versus dorzolamide added to latanoprost in primary open-angle glaucoma subjects. Ophthalmology. 2005;112(4):603-8.
Konstas, A. G., Karabatsas, C. H., Lallos, N., Georgiadis, N., Kotsimpou, A., Stewart, J. A., & Stewart, W. C. (2005). 24-hour intraocular pressures with brimonidine purite versus dorzolamide added to latanoprost in primary open-angle glaucoma subjects. Ophthalmology, 112(4), 603-8.
Konstas AG, et al. 24-hour Intraocular Pressures With Brimonidine Purite Versus Dorzolamide Added to Latanoprost in Primary Open-angle Glaucoma Subjects. Ophthalmology. 2005;112(4):603-8. PubMed PMID: 15808251.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - 24-hour intraocular pressures with brimonidine purite versus dorzolamide added to latanoprost in primary open-angle glaucoma subjects. AU - Konstas,Anastasios G P, AU - Karabatsas,Costas H, AU - Lallos,Nikolaos, AU - Georgiadis,Nikolaos, AU - Kotsimpou,Aikaterini, AU - Stewart,Jeanette A, AU - Stewart,William C, PY - 2004/07/27/received PY - 2004/11/03/accepted PY - 2005/4/6/pubmed PY - 2005/4/15/medline PY - 2005/4/6/entrez SP - 603 EP - 8 JF - Ophthalmology JO - Ophthalmology VL - 112 IS - 4 N2 - OBJECTIVE: To evaluate the 24-hour efficacy of brimonidine purite versus dorzolamide, each added to latanoprost. DESIGN: Double-masked, 2-center, prospective, crossover comparison. PARTICIPANTS: Primary open-angle glaucoma (POAG) subjects. METHODS: Subjects were randomized to brimonidine purite or dorzolamide, each given twice daily, for the first 6-week treatment period after a 6-week latanoprost run-in. Subjects began the opposite treatment for the second 6-week period after a 6-week latanoprost-only treatment between periods. Intraocular pressure (IOP) was measured at 8 am, 12 pm, 4 pm, 8 pm, 12 am, 4 am, and 8 am at each baseline and at the end of each treatment period. This study provided an 80% power that a 1.5-mmHg difference could be excluded between groups if 27 subjects completed the study. A standard deviation (SD) of 2.8 mmHg was assumed. MAIN OUTCOME MEASURES: Twenty-four-hour efficacy of intraocular pressures of brimonidine purite versus dorzolamide, each added to latanoprost. RESULTS: In 31 completed subjects, the baseline mean diurnal 24-hour IOP (+/- SD) was 19.0+/-1.7 mmHg for brimonidine purite and 19.0+/-1.6 mmHg for dorzolamide (P = 0.52). The 8 am IOP after 6 weeks of therapy was 18.4+/-2.1 mmHg for brimonidine purite and 18.9+/-1.9 mmHg for dorzolamide (P = 0.40). The mean diurnal IOP was 16.9+/-1.5 mmHg for brimonidine purite and 16.8+/-1.5 mmHg for dorzolamide (P = 0.66). Dorzolamide caused a more bitter taste (P = 0.01) than brimonidine purite. CONCLUSIONS: This study suggests that brimonidine purite and dorzolamide, added to latanoprost, have similar efficacy and safety in POAG or ocular hypertensive subjects. SN - 1549-4713 UR - https://www.unboundmedicine.com/medline/citation/15808251/24_hour_intraocular_pressures_with_brimonidine_purite_versus_dorzolamide_added_to_latanoprost_in_primary_open_angle_glaucoma_subjects_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0161-6420(04)01789-0 DB - PRIME DP - Unbound Medicine ER -